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and MTG patients. Additionally, hospitalizations in intensive care units (50% SG vs. 
22% MTG patients), emergency visits (21% SG vs. 6% MTG) and the presence of 
adenoma complications (73% SG vs. 44% MTG) constitute a source of cost increment 
in these patients. Patients who accomplish with the most strict study clinical control 
criteria (GH < 1.0 and IGF-1 < 100%) showed the lowest direct cost of illness (c6169 
vs. c12,990). CONCLUSIONS: The economic cost of acromegaly is dependent on the 
clinical control of the disease. Direct cost of illness is the half that the cost in non 
controlled patients.
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APPROVAL AFTER REJECTION—AN INSIGHT IN HTA RE-EVALUATIONS
Sweeney N, Andreykiv M, Wiebinga C
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OBJECTIVES: To gain insight into the re-evaluation process of HTA agencies after 
an initial rejection and identify the adaptations that led to the approval of re-submitted 
dossiers. METHODS: Phase I: manual search of 57 health care agencies’ websites for 
published diabetes-related assessments (January 2007-May 2010). Phase II: the two 
most re-assessed drugs for which detailed information was available were selected for 
further evaluation (insulin glargine and exenatide). For these drugs, all reports pub-
lished prior to 2007 were also included. RESULTS: Phase I identiﬁ ed 117 relevant 
single technology appraisals; 18 were re-evaluations. Six agencies performed re-eval-
uations of the same drug after an initial rejection: CADTH, CVZ, HAS, PBAC, 
AHTAPol and SMC. To date, SMC evaluated 32 submissions for 13 anti-diabetic 
drugs, PBAC published 20 (eight drugs), CADTH 13 (four drugs), CVZ 14 (four 
drugs) and AHTAPol 10 (two drugs). In phase II insulin glargine (four re-submissions 
to PBAC and 1 to CADTH) and exenatide (two re-submissions to PBAC, 1 to CVZ 
and 1 to AHTAPol) were evaluated. It became clear that payers do focus on overall 
cost. The approach that was chosen for those two drugs was to control overall cost 
either by restricting access or by settling on a lower price. CVZ accepted exenatide 
for reimbursement only after restricting access to a subgroup of obese type 2 diabetes 
mellitus patients (with an ICER of c5.231). Instead of patient segmentation PBAC 
insisted on lowering the price for both medications (rationale for insulin glargine being 
concern that prescribing cannot be contained within the deﬁ ned population). 
AHTAPol limited exenatide reimbursement to 50% to control prescribing rates. 
CONCLUSIONS: For the diabetes cases analyzed HTA agencies attempted to control 
health care expenditure by either lowering drug costs or by narrowing the deﬁ nition 
of the target population, the latter inevitably allowing fewer patients access to the 
drug.
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OBJECTIVES: The AOTM in Poland was established to give MoH in Poland advice 
on reimbursement. The aim of this research is to create an overview of HTA reports 
on diabetes compounds in Poland and the results of the decision making. METHODS: 
A search was conducted on the webpage of AOTM (http://www.aotm.gov.pl) for HTA 
reports on the following products: Rosiglitazon, Pioglitazon, Sitagliptin, Vildagliptin, 
Saxagliptin, Exenatide, Liraglutide, Glargine, Detemir, Aspart, Glulisene and Lispro. 
RESULTS: Of a total of 163 reports (published between 2007 and 2010), eight reports 
in Polish language on diabetes were identiﬁ ed and assessed. Two reports can be viewed 
as secondary assessment of regulatory safety discussions. The other six reports assessed 
the implementation of new diabetes compounds with assessment of efﬁ cacy, safety 
and cost-effectiveness of the drugs.Two reports assessed safety concerns associated 
with the risk of cancer and concluded based on EMA and FDA research that no 
increased risk was associated with these agents. Rosiglitazone and Sitagliptin were not 
recommended for reimbursement due to availability of other treatments with similar 
efﬁ cacy. Saxagliptin, Exenatide and Liraglutide got the recommendation to be reim-
bursed due to expected increase in QALYs. The ﬁ nal report was assessing Glulisene 
which got the recommendation to temporary reimburse (2 years) provided that data 
on hard endpoints (not speciﬁ ed in public report) and cost-effectiveness should be 
delivered. CONCLUSIONS: Recommendation by AOTM is supported by assessment 
of available RCTs, cost per life-year gained, cost per QALY, estimated budget impact 
for 5 years and also in some cases reports from EMEA, FDA and other HTA agencies 
(SMC, PBAC and CADTH). The AOTM’s recommendation is not obligatory for the 
Polish Ministry of Health.
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OBJECTIVES: A substantial number of new pharmaceutical treatment strategies have 
been introduced for the treatment of diabetes mellitus type II. The availability of these 
drugs for patients in different countries depends on the evaluation standards and 
methods applied in the various phases of drug assessment. Objective of this research 
was to review the requirements and criteria applied for the assessment of antidiabetic 
drugs along the regulatory process by EMA (Europe) and FDA (USA) for the assess-
ment of efﬁ cacy and safety as well as for reimbursement decisions by NICE (England) 
and IQWiG (Germany) and to compare their consistency, with a special focus on 
IQWiG’s procedures. METHODS: A review of relevant current method documents 
and reports on evaluations of antidiabetic drugs published by IQWiG was conducted. 
These were compared with guidance documents issued by FDA, EMA and NICE with 
respect to endpoints considered in diabetes and their deﬁ nition, criteria for the type 
of evidence, and potential comparators. RESULTS: Consistently, across all agencies 
severe and non-severe hypoglycemias were considered highly relevant. There was, 
however, a substantial heterogeneity in the deﬁ nition of hypoglycaemias. The surro-
gate parameter HbA1C as primary endpoint was accepted by all agencies investigated 
apart from IQWiG. In its assessments, evidence from randomized as well as from 
observational studies was accepted by NICE. For safety evaluations preclinical studies 
were taken into consideration by EMA and FDA in addition to randomized controlled 
trials. IQWiG on the other hand focused exclusively on randomized controlled trials 
for the assessment of effectiveness as well as safety. CONCLUSIONS: There is a 
substantial variation of criteria applied and evidence considered relevant within the 
assessment process of IQWiG compared to other agencies. This might lead to regional 
variations in the availability of drugs. It is important to be aware of the different 
requirements of agencies, when designing trials and planning market access.
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MEDICAL TREATMENTS AND QUALITY OF DIABETIC CARE (TYPE II) 
IN GERMANY ARE DIRECTLY AND INDIRECTLY IMPROVED BY DMPS
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OBJECTIVES: Disease Management Programmes (DMP) aim at improving care 
quality by implementing standards for medical practices. In the case of Diabetes Mel-
litus Type II (DM II), care improvements can be assessed by the duration between the 
ﬁ rst diagnosis and the occurrence of the ﬁ rst related complication. The aim of this 
longitudinal study is to investigate the direct inﬂ uence of the DMP-based treatments 
on patient outcomes, measured as the postponement of diabetes related complications 
in a large population of DM II patients. The study also investigates how DMP inscrip-
tions of some patients of a medical practice indirectly inﬂ uence patient outcomes of 
DM II patients, who are not inscribed in a DMP, but are treated in the same practise. 
We argue that this indirect effect is due to physicians’ learning from the DMP-based 
treatments in their clinics. METHODS: Using consultation data from IMS Health 
from a period of 25 years (1984–2009) a survival analysis is applied. The data set 
includes 161,747 DM II patients from >1100 practices. Applying a Kaplan–Meier–
Method we test for direct effects of DMPs on patient outcomes. By pooling patients 
by the registration year of the practice-leading physician and by focussing on their 
quarterly consultation rate, we test for indirect effects of DMPs on patient outcomes. 
RESULTS: The mean survival time (duration between ﬁ rst diagnosis and ﬁ rst compli-
cation) of the medical treatment of diabetics in a DMP is 14,82 years, differing sig-
niﬁ cantly from the 15,76 years without a DMP. These tests are controlled for 
following patient variables: sex, age, HbA1C, BMI and the insurance status. Learnings 
from DMPs, indirectly affecting DM care, signiﬁ cantly postpone complications for 
younger physicians and practices with fewer diabetics. CONCLUSIONS: Contributing 
to assessments of DMPs, the study discusses policy implications, as it is shown that 
care quality is improved by physicians learning from DMPs.
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OBJECTIVES: To examine the rate and predictors of diabetes monitoring in the US. 
METHODS: This cross-sectional retrospective study was conducted on a representa-
tive, non-institutionalized sample of the US population, using the self-reported infor-
mation from the 2007 Household Component (HC) of the MEPS. According to the 
American Diabetes Association (ADA) 2007 practice guidelines, proper provider 
monitoring is deﬁ ned as at least two A1c tests, one eye and one foot examination 
annually. Health status was measured by SF-12®Version2. a logistic regression model 
was used to examine the predictors of proper monitoring. Differences in health status 
and medical expenditures between patients with and without proper monitoring were 
examined using t-tests. Estimates were weighted to the total population (WTP). 
RESULTS: Among 1,747 (WTP: 19,320,394) patients with diabetes, 80.64% had at 
least two A1c tests; 63.29% had an eye examination; and 67.51% had a foot examina-
tion. Thus, 63.36% patients (WTP: 14,065,289) received proper diabetes monitoring. 
Older patients (OR:1.021, 95% conﬁ dence interval [CI]: 1.012–1.030), non-Hispanic 
Caucasians compared with African American patients (OR: 1.236, 95% CI: 0.933–
1.636), patients with a higher education level (OR:1.211, 95% CI: 1.056–1.390), 
insurance coverage (OR:2.216, 95% CI: 1.408–3.486), use of oral anti-diabetic drugs 
(OR:2.935, 95% CI: 2.131–4.042) and insulin (OR:3.453, 95% CI: 2.477–4.814) 
were more likely to undergo the proper monitoring. Well monitored patients had a 
higher Mental Component Summary score (50.09 ± 0.37 vs. 48.51 ± 0.45, P < 0.05), 
but a lower Physical Component Summary score (39.95 ± 0.34 vs. 42.28 ± 0.47, P < 
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0.05) on the SF 12. Properly monitored patients spent signiﬁ cantly more on total 
health care services (+$5243), outpatient visits (+$1023), and medications (+$1204), 
respectively (all P-values<0.05). CONCLUSIONS: In the US, nearly 40% patients with 
diabetes do not receive the proper diabetes monitoring controlling for racial and 
socioeconomic disparities. Anti-diabetics/insulin use, mental/cognitive status, physical 
health status, and health care expenditure may also interact with performing monitor-
ing. Barriers and cost-beneﬁ t for long-term monitoring should be studied.
PDB90
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BACKGROUND: Advances in screening technology have led to rapid expansion of 
newborn screening as a public health initiative in the United States. Due to variation 
across states in program implementation, there is a lack of standardization and 
accountability, which can affect quality of care. Texas currently screens for 28 disor-
ders. OBJECTIVES: The Texas Newborn Screening Performance Measures Project 
was initiated with the objective of developing evidence-based performance measures 
to improve quality, accountability and uniformity in the care. METHODS: A three 
step approach was used for identiﬁ cation and development of key measures for seven most 
critical disorders: systematic reviews; impact assessment; and feasibility assessment. Impact 
assessments (likert scale) were based on National Quality Measures Clearinghouse™ 
(NQMC) criteria: scientiﬁ c soundness, relevance, health importance, impact on quality of 
care, and ability to address disparities in care. A likert scale was also used for feasibility 
assessment on key aspects: data availability, ease of collection, infrastructure and human 
resource needs, overall cost, and time constraints. RESULTS: A total of 50 performance 
measures were supported by scientiﬁ c evidence. Impact and feasibility assessments led 
to the approval of 33/50 measures. “Time to initiate treatment” received the highest 
scores on potential impact on patient outcomes (mean impact score 86.67/100, SD 
1.5). Other measures with potentially high impact (score >80/100) were: compliance 
with oral prophylactic medication and age at ﬁ rst Prevnar® vaccination in sickle cell 
disease; screening of at-risk family members in fatty acid disorders; frequency of 
growth assessments in congenital adrenal hyperplasia and phenylalanine levels in 
phenylketonuria. “Time to treatment” for individual disorders was also ranked very 
high on feasibility (mean feasibility score 88.67/100, SD 3.88). CONCLUSIONS: This 
is one of the ﬁ rst efforts to identify and develop evidence-based performance measures 
in newborn screening and can pave the way for system wide changes and development 
of national guidelines.
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OBJECTIVES: Investigate the type 2 diabetes mellitus (T2DM) treatment practice and 
achievement of therapeutic goals in a cohort of T2DM patients treated in the Brazilian 
PHCS. METHODS: This is a cross-sectional analysis of 383 T2DM outpatients 
treated in 5 cities covered by the PHCS. Data was collected using information from 
the previous year by interviewing patients using a validated questionnaire comple-
mented by medical chart review. Therapeutic goals suggested by the Brazilian Diabetes 
Society were used as standard treatment. RESULTS: Mean age was 60.5 ± 9.6 years, 
mean BMI 29.1 ± 5.3 Kg/m2 and mean duration of diabetes of 12.2 ± 8.75 years. The 
frequency of associated arterial hypertension was 66.8% (n = 256); obesity 39% n = 
144); dyslipidemia 69.6% (n = 267) and heart failure 5.5% (n = 21). Microvascular 
complications were present in 32.4% (n = 124); 8.1% (n = 31) had macrovascular 
complications; 18% (n = 69) had at least one micro and one macrovascular complica-
tion and 41.5% (n = 159) had no complications. Current treatment practice was: 3.6% 
(n = 14) diet only; 30% (n = 115) monotherapy with oral anti-diabetic (OAD); 37.8% 
(n = 145) combined therapy with more than one OAD agents; 23.2% (n = 89) com-
bined therapy with insulin and 5.2% (n = 20) just insulin. The most prescribed drug 
was metformin (41.4%), followed by insulin (19.1%), sulphonylureas (18.6%), DPP4 
inhibitors (8.7%), TZDs (5.5%), and others (6.7%). Medications for dyslipidemia 
was used by 47.5% (n = 178); cardiovascular drugs in 77.4% (n = 287) and anti-
obesity drugs in 4% (n = 15). Treatment targets were achieved in: 76.8% for systolic 
and diastolic blood pressure (<130 × 85 mmHg), 19.5% for BMI < 25 kg/m2, 28% 
for HDL cholesterol >55 women, 37.3% for HDL cholesterol >45 men and 28.2% 
reached the goal for HbA1c (within normal range). Only 6.8% of the group (n = 26) 
reached all the treatment targets. CONCLUSIONS: The national goals for glycemic 
control, blood pressure and lipid levels are rarely achieved in real-world clinical 
practice, even with the high use of medications. 
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OBJECTIVES: Diabetes mellitus type 2 (T2DM) is a chronically progressive disease 
and the treatment must be selected according to the pathophysiological phase of the 
disease at the time the treatment is begun. The Croatian public diabetology sector 
takes care of approximately 150,000 adults treated with oral hypoglycemic agents 
(OHA) alone or in combination with insulin. Our objective was assessment of the 
clinical and economic consequences of OHA treatment in T2DM from a Croatian 
health care system perspective. METHODS: The target population deﬁ ned for the 
study was diabetic patients treated with OHA alone. Medication consumption was 
quantiﬁ ed by using Pharmis and CroDiab data. a clinical expert panel provided 
resource-use information not available in published literature or health care databases. 
RESULTS: Current consumption data is showing that 62.8% patients are using OHA 
as monotherapy. Within this group, majority is using either biguanides or sulphonyl-
ureas. Patients treated with sulphonylureas are represented with almost the same 
percentage as those treated with biguanides (25% vs. 29%). Combination of two 
OHA is used in 34.2% while 3% of patients are treated by triple therapy. The most 
often choice in dual therapy is combination of biguanides and sulphonylureas while 
biguanides, sulphonylureas and thiazolidinediones in combination as the most favour-
able treatment option in triple therapy. Biguanides are used as a one of OHA in 61% 
of patients. CONCLUSIONS: Considering current clinical guidelines, lifetime beneﬁ ts 
of biguanides and facts that they are low-cost agent, relatively small proportion of 
T2DM patients are treated with this agent in Croatia. Findings of this investigation 
revealed real life pattern of T2DM treatment, which enables directing in better treating 
and more cost-effective management in Croatia.
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THE RELIABILITY OF PROPORTION OF DAYS COVERED 
CALCULATIONS USING DEFINED DAILY DOSE ESTIMATES
Levin R, Papademetriou E, Aubert RE
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OBJECTIVES: Using a large, US administrative pharmacy claims database, calculate 
proportion of days covered (PDC) using actual days supply, and compare estimated 
PDC (ePDC) using days supply derived from drug-speciﬁ c Deﬁ ned Daily Dose (DDD) 
criteria. METHODS: Continuously eligible patients ﬁ lling non-insulin anti-diabetic 
medication were targeted from a large sample of pharmacy claims during 2008 and 
2009. Medications were grouped into ATC diabetes drug classes. Proportion of days 
covered (PDC) was calculated as the number of days a patient had medication in their 
possession divided by the number of days in the period. PDC was ﬁ rst calculated using 
actual days supply, then ePDC was calculated using an estimated days supply from 
DDD, strength, and pill quantity. The percent of patients adherent to therapy was 
deﬁ ned by a PDC > 0.80. The reliability of each method was assessed by Pearson 
correlation coefﬁ cients and agreement above chance was assessed using Kappa statis-
tics. RESULTS: Adherence was calculated for 163,750 patients taking non-insulin 
anti-diabetics. Overall, the PDC was 0.69 and ePDC 0.57. The two measures were 
also highly and signiﬁ cantly correlated (r = 0.73; P < 0.0001). The percent adherent 
was 48.8% (PDC) and 34.4% (ePDC), (Kappa = 0.50; P < 0.0001). At the medication 
class level, differences in PDC and ePDC ranged from 0.01 to 0.35, with correlation 
coefﬁ cients ranging from 0.40 to 0.93. Differences in the percent adherent metric 
ranged from −2.3 to 23.2, and kappa values from 0.22 to 0.89. CONCLUSIONS: 
Applying DDD estimates for the purposes of diabetes adherence estimation when 
lacking days supply values may provide reasonable estimates of adherence based on 
results presented here. At the medication class level there is greater variability in the 
reliability measures. Including claims from the U.S. only is a limitation of this analysis, 
as local treatment patterns may vary, and DDD values were not available for all U.S. 
medications.
PDB94
MARKOV AND MONTE-CARLO MODELS IN THE PROGRESSION OF 
DIABETES MELLITUS: A LITTERATURE REVIEW TO IDENTIIFY THE 
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OBJECTIVES: Markov and Monte-Carlo (MC) models are often used to simulate 
Diabetes Mellitus (DM) and its complications over time, but reasons to choose the 
model type are poorly documented. a systematic literature review was performed to 
identify factors inﬂ uencing the choice of the model type. METHODS: Models simulat-
ing the progression of DM and its complications were selected from Medline and 
Embase databases. Literature reviews, methodological articles and non original models 
were excluded. Each full-paper selected went through a 31-item checklist via a double-
reading process. a qualitative analysis was performed to evaluate the accuracy of the 
model with the study question. RESULTS: Sixty-one models were selected, including 
